Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline furthers cancer drug development

GlaxoSmithKline furthers cancer drug development

2nd November 2005

UK-based pharmaceuticals firm GlaxoSmithKline (GSK) is confident that its new cancer treatment can offer hope to patients.

Arranon is a chemotherapy agent designed to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma patients who have not responded to two chemotherapy regimens.

Patients who fail to respond to chemotherapy or who relapse following the treatment often have a rather poor prognosis.

Following approval from the US Food and Drugs Administration (FDA) GSK hopes that its treatment can help fill this gap.

“Arranon affirms GSK’s long-term commitment to discover drugs for the treatment of cancer and to working with others in the cancer community to develop treatments for even the most difficult to treat malignancies,” a company spokesman said in response to the FDA’s announcement.

“We are proud to meet this critical need and will continue to work closely with the oncology community to evolve the treatment paradigm.”

T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma affects 1,600 adults and children in the US every year.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.